LTGO Latigo Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2056611 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.5%
Debt / equity0.00x
Current ratio29.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $17.50M | $21.23M | — | $22.10M | $22.92M | — |
| SG&A expense | $5.43M | $4.58M | — | $2.63M | $2.82M | — |
| Operating income | -$22.93M | -$25.81M | — | -$24.72M | -$25.75M | — |
| Interest expense | $699,000 | $251,000 | — | $0 | $0 | — |
| Income tax | $0 | $0 | — | $0 | $0 | — |
| Net income | -$20.95M | -$25.80M | -$22.96M | -$24.80M | -$25.84M | -$20.95M |
| EBITDA | -$22.83M | -$25.71M | — | -$24.62M | -$25.64M | — |
| EPS (basic) | -0.55 | -27.59 | — | -29.50 | -36.52 | — |
| EPS (diluted) | -0.55 | -27.59 | — | -29.50 | -36.52 | — |
| Dividends declared per share | 0.00 | — | — | — | — | — |
| Weighted avg. shares (diluted) | 37.84M | 935,025 | — | 840,403 | 707,465 | — |
| Balance sheet | ||||||
| Cash & equivalents | $401.24M | $55.00M | — | $104.64M | $74.50M | — |
| Current assets | $406.44M | $59.20M | — | — | — | — |
| PP&E, net | $440,000 | $457,000 | — | — | — | — |
| Total assets | $408.46M | $64.76M | — | — | — | — |
| Current liabilities | $13.96M | $51.58M | — | — | — | — |
| Total liabilities | $14.48M | $52.26M | — | — | — | — |
| Shareholders' equity | $393.97M | -$276.08M | -$252.58M | -$195.85M | -$173.23M | -$149.08M |
| Shares outstanding | 66.30M | 988,236 | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$19.52M | — | — | -$19.91M | — | — |
| Capital expenditure | $36,000 | — | — | $0 | — | — |
| Free cash flow | -$19.56M | — | — | -$19.91M | — | — |
| Investing cash flow | -$36,000 | — | — | $0 | — | — |
| Financing cash flow | $365.76M | — | — | $50.05M | — | — |
| Depreciation & amortization | $100,000 | $100,000 | — | $100,000 | $100,000 | — |
| Stock-based compensation | $2.54M | $2.14M | — | $1.82M | $1.68M | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.